Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
06 janv. 2016 08h00 HE
|
SteadyMed Therapeutics
VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension
05 janv. 2016 07h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
07 déc. 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting
28 oct. 2015 07h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent
21 oct. 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed to Participate in Upcoming Investor Conferences
02 sept. 2015 07h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed Provides Insights on Recent Corporate Developments and Reports Second Quarter 2015 Financial Results
13 août 2015 16h05 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results
06 août 2015 07h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent
07 juil. 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed and Cardiome Enter Into a License Agreement for the Commercialization Rights to Trevyent(R) Outside the U.S.
29 juin 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif. and VANCOUVER, Canada, June 29, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan...